{"id":"W4205492501","doi":"10.1016/j.jval.2021.11.127","title":"POSB17 Ozanimod for the Treatment of Biologic-Experienced Patients with Moderate-to-Severe Ulcerative Colitis: Results from a Systematic Literature Review and Network Meta-Analyses","year":2022,"lang":"en","type":"article","venue":"Value in Health","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Internal medicine; Tofacitinib; Vedolizumab; Ulcerative colitis; Adalimumab; Infliximab; Ustekinumab; Placebo; Golimumab; Clinical trial; Disease; Pathology; Rheumatoid arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005562566,0.001343311,0.0083566,0.002057013,0.0003476441,0.001858498,0.001023039,0.001261594,0.001897412],"category_scores_gemma":[0.010762,0.0006860616,0.01902716,0.003357694,0.0005951548,0.001094235,0.001037003,0.001776326,0.000155433],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001013119,"about_ca_system_score_gemma":0.001099434,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003183956,"about_ca_topic_score_gemma":0.009316797,"domain_scores_codex":[0.9959748,0.001994516,0.0009327473,0.0005160391,0.0004261423,0.0001557039],"domain_scores_gemma":[0.9939063,0.004002024,0.001451643,0.0002033746,0.0003024075,0.0001343273],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.02163993,0.0001005792,0.01467298,0.1276306,0.8023237,0.000146869,0.00009789026,0.0006864194,0.000575905,0.0001246349,0.0006746963,0.03132588],"study_design_scores_gemma":[0.00359011,0.0006941914,0.01338769,0.005789416,0.9742497,0.00009507856,0.00007052827,0.0002358225,0.0001416002,0.0002000521,0.001514428,0.00003154977],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.03413928,0.9639335,0.0003967261,0.0002367657,0.0001929004,0.0001091018,0.000586743,0.00001706243,0.0003879771],"genre_scores_gemma":[0.6317584,0.3642448,0.001248046,0.00107777,0.000272547,0.0002084964,0.0008810267,0.00002133178,0.000287513],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.0083566,"threshold_uncertainty_score":0.02941799,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05959311009066321,"score_gpt":0.3249714604986568,"score_spread":0.2653783504079936,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}